<DOC>
	<DOCNO>NCT00438958</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor peripheral stem cell transplant bone marrow transplant use stem cell brother sister closely match patient 's stem cell , help stop growth cancer abnormal cell . It also help stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer abnormal cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving colony-stimulating factor , G-CSF , donor help stem cell move bone marrow blood collect store . Giving methotrexate cyclosporine transplant may stop happen . It yet know whether donor peripheral stem cell transplant effective donor bone marrow transplant treat hematologic cancer disease . PURPOSE : This randomized phase III trial study filgrastim-mobilized sibling donor peripheral stem cell transplant see well work compare sibling donor bone marrow transplant treat patient hematologic cancer disease .</brief_summary>
	<brief_title>Sibling Donor Peripheral Stem Cell Transplant Sibling Donor Bone Marrow Transplant Treating Patients With Hematologic Cancers Other Diseases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare time treatment failure patient hematologic malignancy disease treat filgrastim ( G-CSF ) -mobilized matched-sibling donor peripheral blood stem cell transplantation v G-CSF-stimulated matched-sibling donor bone marrow transplantation . Secondary - Compare hematological recovery overall survival patient treat regimen . - Compare quality life , term extensive graft-versus-host disease ( GVHD ) , patient treat regimen . - Compare economic impact associate treatment regimen . Tertiary - Compare incidence severity acute GVHD patient treat regimen . - Compare organ involvement , symptomatology , functional impact chronic GVHD patient treat regimen . - Compare disease-free survival patient treat regimen . - Compare donor quality life . - Compare cost analysis , societal perspective , treatment regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord treatment center , disease ( chronic myelogenous leukemia v acute myeloid leukemia v myelodysplastic syndrome vs hematologic malignancy ) , disease stage ( early disease v late disease ) , condition regimen ( busulfan cyclophosphamide v cyclophosphamide total body irradiation v ) . - Myeloablative conditioning regimen : Patients receive myeloablative conditioning regimen approve clinical chair . - Stem cell transplantation ( SCT ) : Patients randomize 1 2 SCT arm . - Arm I : Patients undergo sibling donor filgrastim ( G-CSF ) -mobilized peripheral blood SCT day 0 . - Arm II : Patients undergo sibling donor G-CSF- mobilize bone marrow transplantation day 0 . - Graft-verus-host disease ( GVHD ) treatment : Patients receive methotrexate IV day 1 , 3 , 6 , 11 cyclosporine IV ( orally ) every 12 hour begin day -2 continue day 100 . Quality life assess baseline 1 3 year post-transplantation . After completion study therapy , patient follow periodically least 4 year . PROJECTED ACCRUAL : A total 230 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one follow hematologic malignancy : Acute myeloid leukemia first complete remission second complete remission Chronic myeloid leukemia chronic accelerate phase Myelodysplasia , include follow : Refractory anemia ( RA ) RA ring sideroblast RA excess blast ( RAEB ) I RAEB transformation Chronic myelomonocytic leukemia Other hematologic malignancy sibling donor stem cell transplantation myeloablative conditioning regimen appropriate , include follow : Indolent nonHodgkin 's lymphoma ( NHL ) Aggressive NHL Chronic lymphocytic leukemia Hodgkin 's lymphoma Myelofibrosis Hematologic malignancy otherwise specify HLAmatched sibling donor available meeting follow criterion : 6/6 HLA match HLA typing perform serologic DNA methodology A B DNA methodology DRB1 ( intermediate resolution ) Not identical twin patient PATIENT CHARACTERISTICS : ECOG performance status 02 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No cognitive , linguistic , emotional difficulty would preclude participation qualityoflife component study Able communicate English French No HIV antibody positivity PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>secondary myelofibrosis</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>